Bromocriptine therapy in chronic schizophrenia: Effects on symptomatology, sleep patterns, and prolactin response to stimulation

F. Brambilla, S. Scarone, L. Pugnetti, R. Massironi, G. Penati, P. Nobile

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Ten chronic schizophrenic patients were given bromocriptine in doses increasing from 1.25 to 5 mg over 6 days (the low-dose therapy) and then up to 40 mg over 15 days (the high-dose therapy). Psychopathological status was assessed using the Brief Psychiatric Rating Scale, twice daily the first 6 days, and every 2 days thereafter. The prolactin (PRL) response to haloperidol stimulation (1 mg i.v.) was measured in five cases before and 3 days after the end of high-dose therapy, and in one patient before and 3 days after the end of low-dose therapy. Electroencephalographic sleep studies were carried out before therapy and every 2 nights during low-dose therapy in five patients, and in two cases during high-dose therapy. Bromocriptine therapy modified neither clinical symptomatology nor sleep patterns. The PRL response to haloperidol after therapy was markedly lower than that before therapy in the five patients treated with high doses, and markedly higher in the single patient tested who was treated only with low-dose therapy.

Original languageEnglish
Pages (from-to)159-169
Number of pages11
JournalPsychiatry Research
Volume8
Issue number3
DOIs
Publication statusPublished - 1983

Fingerprint

Bromocriptine
Prolactin
Schizophrenia
Sleep
Therapeutics
Haloperidol
Brief Psychiatric Rating Scale

Keywords

  • bromocriptine
  • prolactin
  • Schizophrenia
  • sleep

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Bromocriptine therapy in chronic schizophrenia : Effects on symptomatology, sleep patterns, and prolactin response to stimulation. / Brambilla, F.; Scarone, S.; Pugnetti, L.; Massironi, R.; Penati, G.; Nobile, P.

In: Psychiatry Research, Vol. 8, No. 3, 1983, p. 159-169.

Research output: Contribution to journalArticle

Brambilla, F. ; Scarone, S. ; Pugnetti, L. ; Massironi, R. ; Penati, G. ; Nobile, P. / Bromocriptine therapy in chronic schizophrenia : Effects on symptomatology, sleep patterns, and prolactin response to stimulation. In: Psychiatry Research. 1983 ; Vol. 8, No. 3. pp. 159-169.
@article{53840ef60f554fa3a0820785408ca551,
title = "Bromocriptine therapy in chronic schizophrenia: Effects on symptomatology, sleep patterns, and prolactin response to stimulation",
abstract = "Ten chronic schizophrenic patients were given bromocriptine in doses increasing from 1.25 to 5 mg over 6 days (the low-dose therapy) and then up to 40 mg over 15 days (the high-dose therapy). Psychopathological status was assessed using the Brief Psychiatric Rating Scale, twice daily the first 6 days, and every 2 days thereafter. The prolactin (PRL) response to haloperidol stimulation (1 mg i.v.) was measured in five cases before and 3 days after the end of high-dose therapy, and in one patient before and 3 days after the end of low-dose therapy. Electroencephalographic sleep studies were carried out before therapy and every 2 nights during low-dose therapy in five patients, and in two cases during high-dose therapy. Bromocriptine therapy modified neither clinical symptomatology nor sleep patterns. The PRL response to haloperidol after therapy was markedly lower than that before therapy in the five patients treated with high doses, and markedly higher in the single patient tested who was treated only with low-dose therapy.",
keywords = "bromocriptine, prolactin, Schizophrenia, sleep",
author = "F. Brambilla and S. Scarone and L. Pugnetti and R. Massironi and G. Penati and P. Nobile",
year = "1983",
doi = "10.1016/0165-1781(83)90059-8",
language = "English",
volume = "8",
pages = "159--169",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Bromocriptine therapy in chronic schizophrenia

T2 - Effects on symptomatology, sleep patterns, and prolactin response to stimulation

AU - Brambilla, F.

AU - Scarone, S.

AU - Pugnetti, L.

AU - Massironi, R.

AU - Penati, G.

AU - Nobile, P.

PY - 1983

Y1 - 1983

N2 - Ten chronic schizophrenic patients were given bromocriptine in doses increasing from 1.25 to 5 mg over 6 days (the low-dose therapy) and then up to 40 mg over 15 days (the high-dose therapy). Psychopathological status was assessed using the Brief Psychiatric Rating Scale, twice daily the first 6 days, and every 2 days thereafter. The prolactin (PRL) response to haloperidol stimulation (1 mg i.v.) was measured in five cases before and 3 days after the end of high-dose therapy, and in one patient before and 3 days after the end of low-dose therapy. Electroencephalographic sleep studies were carried out before therapy and every 2 nights during low-dose therapy in five patients, and in two cases during high-dose therapy. Bromocriptine therapy modified neither clinical symptomatology nor sleep patterns. The PRL response to haloperidol after therapy was markedly lower than that before therapy in the five patients treated with high doses, and markedly higher in the single patient tested who was treated only with low-dose therapy.

AB - Ten chronic schizophrenic patients were given bromocriptine in doses increasing from 1.25 to 5 mg over 6 days (the low-dose therapy) and then up to 40 mg over 15 days (the high-dose therapy). Psychopathological status was assessed using the Brief Psychiatric Rating Scale, twice daily the first 6 days, and every 2 days thereafter. The prolactin (PRL) response to haloperidol stimulation (1 mg i.v.) was measured in five cases before and 3 days after the end of high-dose therapy, and in one patient before and 3 days after the end of low-dose therapy. Electroencephalographic sleep studies were carried out before therapy and every 2 nights during low-dose therapy in five patients, and in two cases during high-dose therapy. Bromocriptine therapy modified neither clinical symptomatology nor sleep patterns. The PRL response to haloperidol after therapy was markedly lower than that before therapy in the five patients treated with high doses, and markedly higher in the single patient tested who was treated only with low-dose therapy.

KW - bromocriptine

KW - prolactin

KW - Schizophrenia

KW - sleep

UR - http://www.scopus.com/inward/record.url?scp=0020622568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020622568&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(83)90059-8

DO - 10.1016/0165-1781(83)90059-8

M3 - Article

C2 - 6574535

AN - SCOPUS:0020622568

VL - 8

SP - 159

EP - 169

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 3

ER -